MetaCap

Abeona Therapeutics (ABEO) vs Emmis Acquisition (EMIS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Emmis Acquisition (EMIS) has outperformed Abeona Therapeutics (ABEO) over the past year, gaining 4.4% versus a loss of 46.0%. Abeona Therapeutics is the larger company by market cap ($165.3 million vs $163.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABEO-45.98%EMIS+4.39%
+72%+9%-55%
Nov 21, 20251 yearNov 20, 2026
ABEO-55.84%EMIS+4.60%
+37%-12%-60%
Oct 20, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABEO versus EMIS key metrics
MetricABEOEMIS
Share price$2.42$10.36
Market cap$165.31M$163.36M
1-day change-1.22%+0.15%
YTD return-54.08%+4.07%
1-year return-45.98%+4.39%
5-year return-86.74%—
EPS (TTM)$-1.16—
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$5.82M—
Net income (latest FY)$71.18M—
Gross margin73.68%—
Operating margin-1536.91%—
Net margin1223.08%—
52-week high$7.65$10.38
52-week low$2.09$9.92
Distance from 52-week high-68.37%-0.24%
Analyst consensusstrong_buy—
Avg. price target upside+542.98%—
Average volume1.66M16.19K
Shares outstanding68.31M11.94M
Employees226—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EMIS has outperformed ABEO by 50.4 percentage points over the past year.

About Abeona Therapeutics

ABEO stock →

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.

Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees

About Emmis Acquisition

EMIS stock →

Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

Health Care · Biotechnology: Pharmaceutical Preparations

ABEO vs EMIS FAQ

Which is bigger, Abeona Therapeutics or Emmis Acquisition?

Abeona Therapeutics (ABEO) is larger, with a market capitalization of $165.31M compared with $163.36M for Emmis Acquisition (EMIS).

Which stock has performed better over the past year, ABEO or EMIS?

EMIS returned +4.39% over the past 12 months, compared with -45.98% for ABEO (price return, excluding dividends). Past performance does not predict future results.

Are Abeona Therapeutics and Emmis Acquisition in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons